1535 PK/PD data in GBM at ASCO

BET nature.com/articles/s4158…

Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-analysis | Oncology | JAMA | JAMA Network jamanetwork.com/journals/jama/…

FDA-ABTC workshop on drug permeability … candid takes (this from Bill Elmquist) and non-hyperbolic discourse. Worth the Baltimore redeye.

I'm sure no one needs reminding that #ASCO24 abstracts drop today at 5pm ET. Here's a reminder of the key presentations, though we won't see LBAs until the meeting itself oncologypipeline.com/apexonco/asco-… $TNGX $MRUS $IDYA $AZN $JNJ

Monday at #ASCO2024: Niraparib + XRT Phase 0/2 in Newly Diagnosed, MGMT-Unmethylated GBM OS= 20.3 months #Gliofocus Study coming in June: a global, label-enabling, Ivy Brain Tumor Center-sponsored, head-to-head Phase 3 trial in partnership with GSK

Excellent study … PARP trapping is key

#ASCO24 analysis from Roger Stupp practiceupdate.com/expertopinion/…

Important point on the MoA of ADCs by Pat LoRusso. Radiolabeled antibody studies showed <1% of tumor uptake with antibody therapies. Elisabeth de Vries

I think the most impactful CNS oncology data at #ASCO24 … nicely done Mehdi Touat and colleagues. Years from now, CODEL may simply affirm this result.

❗🎉 We received FDA approval to proceed with our Phase 3 clinical trial in partnership w/ GSK! We're accelerating the Gliofocus Study, a global trial comparing niraparib, a PARP1/2 inhibitor, against TMZ for newly diagnosed MGMT-unmethylated #GBM. 📰: loom.ly/ckeho64

GBM cell states are fluid, but manipulable

Very inspiring talk by dr McDermott on Radiotherapy response and resistance of meningiomas at the International Neurosurgical Forum in Rome. Happy to see so many groups working on that Sahm Lab RaleighLab EORTC EANO

As we celebrate the approval of vorasidenib for treatment of grade II IDH-mutant, I would like to recognize those that developed the original compounds. See pubs.acs.org/doi/10.1021/ac…, science.org/doi/10.1126/sc… and perhaps most importantly pubs.acs.org/doi/full/10.10…. Fantastic job!

So great to have three of Ivy Brain Tumor Center researchers be part of this amazing @abta community. An-Chi Tien Charuta Furey, MD and Artak Tovmasyan 👏🏻🧠

That Dr. Spetzler flew in for this remains a source of personal pride. His legacy of inquiry, integrity, and leadership is a North Star for all of us.

What's new in the treatment of GBM? Great talk of Lombardi Giuseppe in Bologna chaired by Emilie Le Rhun, Antonio Silvani and dr Sturiale.. looking at new trials with PARP inhibitor Niraparib and other new agents EORTC EANO Nader Sanai Sapienza Università di Roma